It inhibits the intracellular kinase activity of the vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, VEGFR3 as well as other RTKs involved in pathogenic neoangiogenesis, tumor growth, and metastasis in RCC. Here, VEGFA is linked to renal cell carcinoma.